Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)

被引：0
|
作者：
Weinberg, B. [1 ]
He, A. [1 ]
Tan, B. [2 ]
Turk, A. [3 ]
Noel, M. [1 ]
Marshall, J. [1 ]
Sung, M. [4 ]
Wang, H. [1 ]
Ferguson, C. [1 ]
Swanson, N. [1 ]
Pedersen, K. [2 ]
机构：
[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Indiana Univ Sch Med, Dept Hematol Oncol, Indianapolis, IN USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [1] Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)
    Weinberg, Benjamin Adam
    Wang, Hongkun
    Pedersen, Katrina
    Sehdev, Amikar
    Sung, Max W.
    Hwang, Jimmy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Yoo, C.
    Kim, K-P.
    Kim, I.
    Kang, M. J.
    Cheon, J.
    Kang, B. W.
    Ryu, H.
    Jeong, J.
    Lee, J. S.
    Kim, K. W.
    Ryoo, B-Y.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S565
  • [3] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Kim, I-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1464 - S1464
  • [4] Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin
    Mukherjee, Sarbajit
    Pattnaik, Harsha
    Sonti, Sahithi
    Ramesh, Mrinalini
    Jain, Prantesh
    Ramirez, Robert A.
    Fountzilas, Christos
    Vadehra, Deepak
    Attwood, Kristopher
    Iyer, Renuka
    CANCERS, 2025, 17 (02)
  • [5] Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Belanger, B.
    Bayever, E.
    de Jong, F.
    von Hoff, D. D.
    Siveke, J. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO
    Ettrich, T. J.
    Perkhofer, L.
    Berger, A. W.
    Seufferlein, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer
    Alese, Olatunji B.
    Gbolahan, Olumide B.
    Diab, Maria
    Botrus, Gehan
    Coleman, Kathleen
    McCook-Veal, Ashley
    Liu, Yuan
    Shaib, Walid Labib
    Wu, Christina
    Akce, Mehmet
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345